

Ampio Pharmaceuticals, Inc.  
Form 8-K  
December 10, 2018

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): December 7, 2018**

**AMPIO PHARMACEUTICALS, INC.**

**(Exact name of registrant as specified in Charter)**

<b>Delaware</b>	<b>001-35182</b>	<b>26-0179592</b>
<b>(State or other jurisdiction of</b>	<b>(Commission</b>	<b>(IRS Employer</b>
<b>incorporation or organization)</b>	<b>File No.)</b>	<b>Identification No.)</b>

**373 Inverness Parkway, Suite 200**

**Englewood, Colorado 80112**

**(Address of principal executive offices, including zip code)**

**(720) 437-6500**

**(Registrant's telephone number, including area code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



**Item 1.01 Entry into a Material Definitive Agreement.**

As previously reported, on August 9, 2018, Ampio Pharmaceuticals, Inc. (the “Company”) entered into an underwriting agreement, as amended by Amendment No. 1 thereto dated August 10, 2018, with Canaccord Genuity LLC as the sole underwriter, pursuant to which the Company issued, among other things, warrants (the “Warrants”) to purchase up to 20,000,000 shares of the Company’s common stock, par value \$0.0001 per share (“Common Stock”), with an exercise price of \$0.40 per share.

On December 7, 2018, the Company entered into a Warrant Exercise Agreement (the “Exercise Agreement”) with a certain holder of the Warrants (the “Exercising Holders”), which Exercising Holder owns Warrants exercisable for 3,450,000 shares of Common Stock. Pursuant to the Exercise Agreement, the Exercising Holder and the Company agreed that the Exercising Holder would exercise their Warrants with respect to 1,725,000 shares of Common Stock underlying such Warrants for a reduced exercise price equal to \$0.30 per share.

The Company expects to receive aggregate gross proceeds of approximately \$517,500 from the exercise of the Warrants by the Exercising Holder. In addition, the exercise will result in the reduction of warrants to purchase Common Stock of the Company by approximately 7% and is not dilutive to existing security holders of the Company calculated on a fully diluted basis for outstanding warrants.

The description of the Exercise Agreement set forth herein does not purport to be complete and is qualified in its entirety by reference to the full text of the form of Exercise Agreement attached hereto as Exhibit 10.1.

**Item 3.03 Material Modification to Rights of Security Holders.**

The information contained above in Item 1.01 is hereby incorporated by reference into this Item 3.03.

**Item 9.01 Financial Statements and Exhibits.**

Exhibit Number Description

10.1                    Form of Warrant Exercise Agreement



**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**AMPIO  
PHARMACEUTICALS, INC.**

By: /s/ Thomas E. Chilcott, III  
Thomas E. Chilcott, III  
*Chief Financial Officer*

Dated: December 10, 2018